Optimal timing for surgery after adriamycin treatment in rats.
OBJECTIVE
To determine the optimal timing of surgery after adriamycin treatment, we investigated the time-related effect of adriamycin on wound healing over a long period.


METHODS
We divided 119 female Sprague-Dawley rats into seven treatment groups. Group 1 was subjected to laparatomy only. All the other groups were given 8 mg/kg adriamycin intravenously followed by laparotomy on the same day (group 2), 7 days later (group 3), 14 days later (group 4), 21 days later (group 5), 28 days later (group 6), or 35 days later (group 7). On postoperative day 7, the sutures were removed, abdominal bursting pressure was measured, and tissue samples were taken for histopathological evaluation and analysis of hydroxyproline content.


RESULTS
Bursting pressures were significantly lower in groups 3, 4, 5, and 6 than in group 1. The hydroxyproline content and histopathological evaluation supported these findings.


CONCLUSIONS
Our results showed that the optimal timing for surgery after adriamycin treatment is before the 7th day or after the 35th day. If surgery is performed between these days, there is a high risk of impaired wound healing.
Gulcelik
Mehmet Ali
MA
Department of General Surgery, Ankara Oncology Training and Research Hospital, Ankara, Turkey.
Dinc
Soykan
S
Gulcelik
Nese Ersoz
NE
Cetinkaya
Kadir
K
Caydere
Muzaffer
M
Ustun
Huseyin
H
Alagol
Haluk
H
D034861:Abdominal Wall / Q000473:pathology*; D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology*; D004334:Drug Administration Schedule; D005260:Female; D007150:Immunohistochemistry; D007262:Infusions, Intravenous; D007813:Laparotomy / Q000379:methods*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D012680:Sensitivity and Specificity; D013530:Surgical Wound Infection / Q000517:prevention & control; D013997:Time Factors; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
D004317:Doxorubicin